
Selected publications from PubMed
Semaglutide in patients with hidradenitis suppurativa and obesity.
Nicolau J, Sanchís P, Nadal A, Isabel Tamayo M, Sfondrini G, Grimalt M, García P, Nadal C, Masmiquel L
Med Clin (Barc). 2026 May;166(5):107405 doi: 10.1016/j.medcli.2026.107405.
Dermatological and metabolic benefits of semaglutide in psoriasis with obesity: a 6-month prospective cohort study.
Nicolau J, Nadal A, Sanchís P, Pujol A, Tamayo MI, Sfondrini G, Grimalt M, García P, Nadal C, Masmiquel L
Clin Exp Dermatol. 2026 Feb 24;51(3):442-450 doi: 10.1093/ced/llaf473.
Biomimetic organo-hydrogels reveal the adipose tissue local mechanical anisotropy regulates ovarian cancer invasion.
Gonzalez-Molina J, Nabili P, Marciano D, Abdelnabi S, Gultekin O, Rasul MF, Zhang Y, Nadal C, Chrysanthou A, Alkasalias T, Salehi S, Balkwill F, Lehti K, Gautrot JE
Nat Commun. 2025 Sep 29;16(1):8541 doi: 10.1038/s41467-025-62296-7.
Correction to "BMP-Binding Polysulfonate Brushes to Control Growth Factor Presentation and Regulate Matrix Remodelling".
Hernandez Marchena M, Lambert E, Bogdanović B, Quadir F, Neri-Cruz CE, Luo J, Nadal C, Migliorini E, Gautrot JE
ACS Appl Mater Interfaces. 2025 Jul 23;17(29):42487 doi: 10.1021/acsami.5c12879.
Effects of six months treatment with liraglutide among patients with psoriasis and obesity, beyond metabolic control?
Nicolau J, Nadal A, Sanchís P, Pujol A, Tamayo MI, Nadal C, Masmiquel L
Med Clin (Barc). 2025 Jun 13;164(11):106941 doi: 10.1016/j.medcli.2025.106941.
Help your network discover Dr. Cristina Nadal's clinical expertise.